Adebrelimab
Adebrelimab is Hengrui's PD-L1 antibody, approved in China for first-line extensive-stage small cell lung cancer on the CAPSTONE-1 trial.
Overview
CAPSTONE-1 randomised 462 patients with extensive-stage small cell lung cancer to adebrelimab or placebo with carboplatin and etoposide: median overall survival 15.3 versus 12.8 months (hazard ratio 0.72), among the largest survival gains reported for a PD-L1 antibody in this disease. The NMPA approved the combination in March 2023. Hengrui is testing adebrelimab in limited-stage disease after chemoradiotherapy and with its own ADCs.
Compare all products across the US, EU, UK, Japan, China and Australia →
Approvals
| Region | Year | Indication |
|---|---|---|
| China | 2023 | First-line extensive-stage small cell lung cancer with carboplatin and etoposide (CAPSTONE-1) |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials in OnCo
Latest papers
topQuery for this drug: (TITLE:"Adebrelimab" OR ABSTRACT:"Adebrelimab" OR TITLE:"Arelili" OR ABSTRACT:"Arelili" OR TITLE:"SHR-1316" OR ABSTRACT:"SHR-1316") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Adebrelimab, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductEnvafolimab
Shares PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-L1, Monoclonal antibodies, Immune checkpoint inhibitors and the tag china.
- ProductSugemalimab
Shares PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-L1, Monoclonal antibodies, Immune checkpoint inhibitors and the tag china.
- TrialCameL
Shares Jiangsu Hengrui Pharmaceuticals, Immune checkpoint inhibitors and the tag china.
- ProductAnlotinib
Shares Ying Cheng, Small-cell lung cancer and the tag china.
- ProductSintilimab
Shares PD-1 / PD-L1 immune checkpoint & T-cell activation, Monoclonal antibodies, Immune checkpoint inhibitors and the tag china.
- PersonPiaoyang Sun
Shares Jiangsu Hengrui Pharmaceuticals and the tag china.
- ProductDalpiciclib
Shares Jiangsu Hengrui Pharmaceuticals and the tag china.
- TrialDAWNA-1
Shares Jiangsu Hengrui Pharmaceuticals and the tag china.